Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

12 Aug 2013 07:00

RNS Number : 4202L
ReNeuron Group plc
12 August 2013
 

 

DTR3

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS/ PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

ReNeuron Group plc

2.

State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.2R; or (ii) a disclosure made in accordance with LR 9.8.6R(1); or (iii) in accordance with section 793 of the Companies Act 2006

 

(i)

 

3.

Name of person discharging managerial responsibilities/director

 

Dr. Paul Harper

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3

and identify the connected person

 

Director named in 3.

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 1

 

Interest of person named in 3

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

Ordinary Shares

 

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

Person named in 3

 

8.

State the nature of the transaction

 

Placing of Ordinary Shares

9.

Number of shares, debentures or financial instruments relating to shares acquired

 

Acquisition of 200,000 Ordinary Shares

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

 

0.011%

 

11.

Number of shares, debentures or financial instruments relating to shares disposed

 

 

 

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

 

 

13.

Price per share or value of transaction

 

2.5 pence per Ordinary Share

 

14.

Date and place of transaction

 

9 August 2013

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

Dr. Paul Harper is interested in a total of 451,709 Ordinary Shares in the Company representing approximately 0.025% of issued Ordinary Shares.

 

16.

Date issuer informed of transaction

 

9 August 2013

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

 

17.

Date of grant

 

 

18.

Period during which or date on which it can be exercised

 

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

 

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

 

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

 

See table of options held by Dr. Paul Harper below:

 

 

 

Number of options

Exercise Price

End of Exercise Period

98,781

12.65p

August 2015

98,688

5.07p

August 2016

258,098

12.2p

August 2017

226,682

4.85p

August 2019

277,797

4.43p

August 2020

417,274

4.31p

August 2021

500,000

3.3pp

August 2022

1,877,300

24.

Name of contact and telephone number for queries

 

Pat Huggins, Reneuron Group Plc

+44 (0)1483 302560

 

 

Name of authorised official of issuer responsible for making notification:

 

Patrick Huggins, Head of Finance and Company Secretary

 

Date of notification: 9 August 2013

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFEETIIAIIV
Date   Source Headline
1st Feb 20219:55 amRNSTotal Voting Rights
15th Jan 20212:06 pmRNSSecond Price Monitoring Extn
15th Jan 20212:01 pmRNSPrice Monitoring Extension
15th Jan 20217:00 amRNSClinical Update
6th Jan 20217:00 amRNSAnalyst Conference Call
18th Dec 20204:36 pmRNSPrice Monitoring Extension
18th Dec 20207:00 amRNSNotification of Major Holdings
17th Dec 202012:44 pmRNSNotification of Major Holdings
17th Dec 20207:00 amRNSNotification of Major Holdings
17th Dec 20207:00 amRNSNotification of Allowance granted for US Patent
16th Dec 20205:37 pmRNSNotification of Major Holdings
16th Dec 20202:17 pmRNSNotification of Major Holdings
16th Dec 20207:00 amRNSNotification of Major Holdings
11th Dec 202010:33 amRNSResult of General Meeting and Total Voting Rights
11th Dec 20207:00 amRNSResult of Open Offer
25th Nov 20204:41 pmRNSSecond Price Monitoring Extn
25th Nov 20204:36 pmRNSPrice Monitoring Extension
25th Nov 20202:06 pmRNSSecond Price Monitoring Extn
25th Nov 20202:00 pmRNSPrice Monitoring Extension
25th Nov 202011:05 amRNSSecond Price Monitoring Extn
25th Nov 202011:00 amRNSPrice Monitoring Extension
24th Nov 20204:41 pmRNSSecond Price Monitoring Extn
24th Nov 20204:36 pmRNSPrice Monitoring Extension
24th Nov 20202:06 pmRNSSecond Price Monitoring Extn
24th Nov 20202:00 pmRNSPrice Monitoring Extension
24th Nov 20207:15 amRNSResult of Placing and Subscription and GM Notice
24th Nov 20207:00 amRNSInterim Results
23rd Nov 20205:42 pmRNSProposed Placing, Subscription and Open Offer
2nd Nov 20207:00 amRNSTotal Voting Rights
10th Sep 20203:59 pmRNSResult of AGM
10th Sep 20207:00 amRNSAGM Trading Update
1st Sep 20207:00 amRNSBlock Listing Review and Total Voting Rights
18th Aug 20207:00 amRNSPosting of Annual Report and Notice of AGM
12th Aug 20207:00 amRNSChanges to Non-Executive Board
3rd Aug 20207:00 amRNSTotal Voting Rights
31st Jul 20207:00 amRNSNotification of Allowance granted for US Patent
20th Jul 20207:00 amRNSPreliminary Results
14th Jul 20203:06 pmRNSNotification of Major Holdings
29th Jun 20207:00 amRNSFurther Positive Data in Retinal Clinical Trial
25th Jun 20207:00 amRNSNew Exosome Research Collaboration
17th Jun 20207:00 amRNSRegulatory Approvals and Programme Update
7th May 20207:00 amRNSCTX cell line shows further potential
7th Apr 20202:06 pmRNSSecond Price Monitoring Extn
7th Apr 20202:00 pmRNSPrice Monitoring Extension
7th Apr 202011:06 amRNSSecond Price Monitoring Extn
7th Apr 202011:00 amRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSExosome Research Collaboration
3rd Apr 20207:00 amRNSCOVID-19 Update
16th Mar 20204:43 pmRNSSecond Price Monitoring Extn
16th Mar 20204:39 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.